John L. Brottem Sells 32,930 Shares of Outset Medical, Inc. (NASDAQ:OM) Stock

Outset Medical, Inc. (NASDAQ:OM) General Counsel John L. Brottem sold 32,930 shares of Outset Medical stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $0.80, for a total value of $26,344.00. Following the completion of the transaction, the general counsel now owns 181,188 shares in the company, valued at $144,950.40. The trade was a 15.38 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Outset Medical Stock Performance

NASDAQ OM opened at $0.86 on Friday. The company’s fifty day moving average is $1.01 and its two-hundred day moving average is $1.28. Outset Medical, Inc. has a 52-week low of $0.44 and a 52-week high of $5.22. The company has a debt-to-equity ratio of 4.12, a current ratio of 6.49 and a quick ratio of 5.04. The firm has a market capitalization of $45.18 million, a price-to-earnings ratio of -0.31 and a beta of 2.05.

Institutional Investors Weigh In On Outset Medical

A number of institutional investors have recently added to or reduced their stakes in OM. Vanguard Personalized Indexing Management LLC bought a new stake in shares of Outset Medical in the 2nd quarter worth approximately $49,000. National Bank of Canada FI raised its stake in shares of Outset Medical by 79.2% in the third quarter. National Bank of Canada FI now owns 52,407 shares of the company’s stock valued at $35,000 after purchasing an additional 23,164 shares in the last quarter. Huntington National Bank lifted its position in Outset Medical by 46.2% in the third quarter. Huntington National Bank now owns 63,306 shares of the company’s stock worth $43,000 after purchasing an additional 20,000 shares during the period. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Outset Medical during the second quarter worth $259,000. Finally, Squarepoint Ops LLC increased its holdings in Outset Medical by 74.1% in the 2nd quarter. Squarepoint Ops LLC now owns 80,300 shares of the company’s stock valued at $309,000 after buying an additional 34,187 shares during the period.

Analysts Set New Price Targets

Separately, Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $3.00 target price on shares of Outset Medical in a report on Tuesday, January 7th.

Outset Medical Company Profile

Outset Medical, Inc, a medical technology company, engages in the development of a hemodialysis system for hemodialysis in the United States. The company offers Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings; and manufactures, supports, and distributes for Tablo console, Tablo cartridge, and other consumables.